Esperion Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ESPR research report →
About the company
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
- CEO
- Sheldon L. Koenig
- IPO
- 2013
- Employees
- 304
- HQ
- Ann Arbor, MI, US
Price Chart
- Market Cap
- $656.99M
- P/E
- -130.58
- P/S
- 1.57
- P/B
- -2.58
- EV/EBITDA
- 18.88
- Div Yield
- 0.00%
- Gross Margin
- 65.00%
- Op Margin
- 18.12%
- Net Margin
- -1.77%
- ROE
- 1.99%
- ROIC
- 30.77%
- Revenue
- $403.13M · 21.31%
- Net Income
- $-22,682,000 · 56.17%
- EPS
- $-0.11 · 60.71%
- Op Income
- $60.27M
- FCF YoY
- 45.38%
- 52W High
- $4.18
- 52W Low
- $1.10
- 50D MA
- $2.97
- 200D MA
- $3.04
- Beta
- 1.07
- Avg Volume
- 13.22M
Get TickerSpark's AI analysis on ESPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Looker Benjamin | sell | 11,824 |
| Jun 17, 26 | Koenig Sheldon L. | sell | 53,588 |
| Jun 17, 26 | Halladay Benjamin | sell | 10,773 |
| May 28, 26 | THOMPSON JOHN CRAIG | other | 79,873 |
| May 28, 26 | Shepard Jay | other | 79,873 |
| May 28, 26 | Hoffman Robert E. | other | 79,873 |
| May 28, 26 | Fischer Seth H. Z. | other | 79,873 |
| May 28, 26 | CARROLL J MARTIN | other | 79,873 |
| Mar 17, 26 | Looker Benjamin | sell | 5,708 |
| Mar 17, 26 | Koenig Sheldon L. | sell | 25,578 |
Our ESPR coverage
Recent articles, reports, and earnings notes.
No research on ESPR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ESPR report →Similar companies
Peers in the same neighborhood.